SLC5A2 and diabetic kidney disease: These therapeutic effects would be due to the systemic fasting–like state by SGLT2 inhibitors, but SGLT2 inhibitors would affect locally and directly on proximal tubular cells, for SGLT2 is abundantly expressed in proximal tubular cells, and it becomes over-upregulated in DKD (Umino et al., 2018).